Bacil Pharma Plans ₹50 Cr Rights Issue, Two Directors Resign

Bacil Pharma Ltd announced a board meeting where it approved a Rights Issue of equity shares to raise up to ₹50 crore. The company also approved an increase in its authorized share capital to ₹65 crore. Intermediaries for the Rights Issue, including a registrar, banker, and monitoring agency, were appointed. Additionally, the board accepted the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, citing pre-occupation with other assignments. A Rights Issue Committee was formed, and Ms. Chaitali Kalpataru Shah, Executive Director & CFO, was authorized to handle related documentation. The trading window remains closed until 48 hours after the board meeting outcome.